title: The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide.
abstract: Focal adhesion is known to be highly expressed and activated in glioma cells. Recently, we demonstrated that FAK autophosphorylation inhibitor, Y15 significantly decreased tumor growth of DBTRG and U87 cells, especially in combination with temozolomide. In the present report, we performed gene expression analysis in these cells to reveal genes affected by Y15, temozolomide and combination of Y15 and temozolomide. We tested the effect of Y15 on gene expression by Illumina Human HT12v4 microarray assay and detected 8087 and 6555 genes, which were significantly either up- or down-regulated by Y15-treatment in DBTRG and U87 cells, respectively (p<0.05). Moreover, DBTRG and U87 cells treated with Y15 changed expression of 1332 and 462 genes more than 1.5 fold, p<0.05, respectively and had 237 common genes affected by Y15. The common genes up-regulated by Y15 included GADD45A, HSPA6 (heat-shock 70); DUSP1, DUSP 5 (dual-phosphatase 5); CDKN1A (p21) and common down-regulated genes included kinesins, such as KIF11, 14, 20A, 20B; topoisomerase II, TOP2A; cyclin F; cell cycle protein: BUB1; PARP1, POLA1. In addition, we detected genes affected by temozolomide and by combination of Y15 and temozolomide treatment in U87 cells. Among genes up-regulated by Y15 and temozolomide more significantly than by each agent alone were: COX7B; interferon, gamma-inducible transcript: IFI16; DDIT4; GADD45G and down-regulated: KIF3A, AKT1; ABL; JAK1, GLI3 and ALDH1A3. Thus, microarray gene expression analysis can be effective in establishing genes affected in response to FAK inhibitor alone and in response to combination of Y15 with temozolomide that is important for glioblastoma therapy.
authors: Grace
authors: G
authors: Huang
authors: Baotran
authors: B
authors: Ho
authors: Jeffrey
authors: J
authors: Conroy
authors: Song
authors: S
authors: Liu
authors: Hu
authors: H
authors: Qiang
authors: Department of Surgical Oncology Roswell Park Cancer Institute, Buffalo, NY, 14263, USA. Vita.Golubovskaya@roswellpark.org.
authors: Vita
authors: V
authors: Golubovskaya
mesh_terms: D000814:Aniline Compounds / Q000494:pharmacology*; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D045744:Cell Line, Tumor / Q000187:drug effects; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004347:Drug Interactions; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D015870:Gene Expression / Q000187:drug effects*; D020869:Gene Expression Profiling; D005909:Glioblastoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D046228:Microarray Analysis; D010766:Phosphorylation; D000077204:Temozolomide
chemical_list: C539551:1,2,4,5-benzenetetraamine; D000814:Aniline Compounds; D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D051416:Focal Adhesion Protein-Tyrosine Kinases; D000077204:Temozolomide
references: Anticancer Agents Med Chem. 2011 Sep;11(7):617-9
references: 21355845
references: Oncogene. 2005 Jul 14;24(30):4741-53
references: 15897902
references: Int J Cancer. 2012 Apr 15;130(8):1844-54
references: 21618518
references: Blood. 2009 Jan 29;113(5):1184-91
references: 18927432
references: Front Biosci (Landmark Ed). 2010 Jun 01;15:901-12
references: 20515733
references: Cell Cycle. 2010 Mar 1;9(5):1005-15
references: 20160475
references: Int J Cancer. 2009 Oct 1;125(7):1735-8
references: 19521985
references: Cancer Res. 2009 Oct 15;69(20):8035-42
references: 19789344
references: Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3744-8
references: 8170981
references: J Med Chem. 2008 Dec 11;51(23):7405-16
references: 18989950
references: Biochem J. 2009 Mar 15;418(3):475-89
references: 19228121
references: In Vitro Cell Dev Biol. 1992 Sep-Oct;28A(9-10):609-14
references: 1331021
references: Nat Rev Cancer. 2012 Jul 24;12(8):527-39
references: 22825217
references: Cancer Res. 2002 May 1;62(9):2699-707
references: 11980671
references: Mol Cell Biol. 2006 May;26(10):3853-63
references: 16648480
references: Cell Cycle. 2009 Aug;8(15):2435-43
references: 19571674
references: Mol Cancer Ther. 2007 Apr;6(4):1357-67
references: 17431114
references: Mol Cancer Ther. 2013 Feb;12(2):162-72
references: 23243059
references: Oncogene. 2003 Jun 26;22(26):4035-46
references: 12821938